Increased net sales, growing pipeline highlight Alcon’s first solo year

Growing net sales, an expanding pipeline of therapies, and newly introduced and FDA approved technologies highlighted Alcon’s first year as an independent company.
The year saw a strong growth in net sales, reaching nearly $7.4 billion, up 5% from 2018, and the new product launch of PanOptix in the United States, David J. Endicott, CEO of Alcon, told Ocular Surgery News.
“Last year was a remarkable milestone in Alcon’s history. We completed our spinoff to become an independent company and delivered strong growth in net sales and improved core profitability. (Read more...)